PAL 0.00% 29.5¢ palla pharma limited

News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer, page-9

  1. 2,384 Posts.
    lightbulb Created with Sketch. 264
    In my opinion no capital raising is to be expected. Their debt levels are a bit high especially with the new debt from SOL but it should be considered manageable at the present moment. Profits should be OK to cover debt and interest.

    "Expectations of a modest Operating EBITDA profit for 1H2019 compared to an Operating EBITDA loss of $1.8 million for the prior corresponding period despite the incurrence of non‐recurring legal expenses and an increased investment in research and development."

    Last year result was a loss around 5 million.
 
watchlist Created with Sketch. Add PAL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.